July 24, 2020 – Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health (Dallas, TX), announced it is accelerating its pace of bringing clinical trials online for research initiatives to combat COVID-19.
“Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices,” the health system said in a press release.
“After bringing five clinical trials online in the early days of the virus’ impact, our COVID-19 therapeutic task force and our four institutional review boards have now approved more than 20 COVID-19 research initiatives. We have an unwavering commitment to helping our communities navigate the uncertainty of this virus,” said Jaime Walkowiak, chief research executive, Baylor Scott & White…